---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-24-000008"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T10:37:29.965930+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience FY2023 net loss $36.3M; cash ~$210M post-IPO; Phase 2b MDD studies on track

## Summary
- Net loss $36.3M in FY2023 (vs $27.7M in 2022); R&D spend $30.3M, G&A $7.5M.
- Cash $82.5M at Dec 31, 2023; post-IPO net proceeds ~$133M, cash ~$210M as of Feb 29, 2024.
- ALTO-100 Phase 2b MDD enrollment ongoing; topline data 2H 2024. ALTO-300 Phase 2b data 1H 2025.
- Appointed Drs. Maha Radhakrishnan (ex-Biogen CMO) and Husseini Manji (ex-J&J) to board.
- CIRM approved $15M grant for ALTO-100 Phase 2b in bipolar depression; initiation planned 2024 subject to terms.

## SEC filing metadata
- accession: 0001999480-24-000008
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/0001999480-24-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/alto-form8xk.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-24-000008
- JSON: https://secwatch.observer/filing/0001999480-24-000008.json
- Plain text: https://secwatch.observer/filing/0001999480-24-000008.txt

## Key facts
- Earnings Releases
  Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2023.
  - Period: full year ended December 31, 2023
  - Result: reported results
  source text: On March 21, 2024, Alto Neuroscience, Inc. (the "Company") reported financial results for the full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000008/0001999480-24-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.